CPX-351 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
Status:
Completed
Trial end date:
2017-12-18
Target enrollment:
Participant gender:
Summary
This phase 2 clinical trial studies how well CPX-351 (liposomal cytarabine-daunorubicin)
works in treating patients with relapsed or refractory acute myeloid leukemia or
myelodysplastic syndrome. Drugs used in chemotherapy, such as CPX-351, work in different ways
to stop the growth of cancer cells, either by killing the cells or by stopping them from
dividing.